Several clinically active agents targeting TOP2A, such as etoposide, doxorubicin, and mitoxantrone, have shown promise as a therapy for solid tumors and hematologic cancers [49,50]. The gene discussed is TOP2A; the disease is hematopoietic and lymphoid cell neoplasm.